GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » 5-Year EBITDA Growth Rate

INBP (Integrated Biopharma) 5-Year EBITDA Growth Rate : -22.10% (As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma 5-Year EBITDA Growth Rate?

Integrated Biopharma's EBITDA per Share for the three months ended in Sep. 2024 was $0.03.

During the past 12 months, Integrated Biopharma's average EBITDA Per Share Growth Rate was 85.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -42.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -22.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Integrated Biopharma was 109.90% per year. The lowest was -42.90% per year. And the median was 9.30% per year.

Competitive Comparison of Integrated Biopharma's 5-Year EBITDA Growth Rate

For the Packaged Foods subindustry, Integrated Biopharma's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Biopharma's 5-Year EBITDA Growth Rate Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's 5-Year EBITDA Growth Rate falls into.


Integrated Biopharma 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Integrated Biopharma  (OTCPK:INBP) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Integrated Biopharma 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
BOF NCRA BABB ATPC DDC IMG HCWC NXMH TOFB RKDA XSWX:NESN XPAR:BN KHC GIS SHSE:603288 K NSE:NESTLEIND SHSE:600887 SZSE:300999 MKC
Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Website
https://ir.ibiopharma.com
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from Contract Manufacturing segment which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431